All In Biotech

Drug Trial Radar · NCT06433557

A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia

A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children With Achondroplasia

Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

22

Actual

Start

Jul 26, 2024

Primary completion

Nov 14, 2025

Study completion Nov 2027

Sponsor

Sponsor type
Industry
First posted
May 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This proof-of-concept trial is being conducted to evaluate the efficacy, safety and tolerability of combination treatment with navepegritide and lonapegsomatropin administered as separate subcutaneous (SC) injections once weekly in children with achondroplasia (ACH) aged 2 to 11 years.

Conditions

  • Achondroplasia

Interventions

  • Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injectionsDrug

    For navepegritide, a once weekly s.c. dose of 100 μg CNP/kg. For lonapegsomatropin, a once weekly s.c. dose of lonapegsomatropin 0.30 mg hGH/kg as starting dose. Treatment duration of up to 156 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized growth velocityTime frame: Week 52
  2. Treatment-emergent adverse events (TEAEs).Time frame: Throughout the trial for 156 weeks

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • Ascendis Pharma Investigational Site

    Copenhagen, Denmark

  • Ascendis Pharma Investigational Site

    Dublin, Ireland

  • Ascendis Pharma Investigational Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.